With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.

In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.

Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.

The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.

Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.

In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.

In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.

The monoclonal antibody, Brelovitug, met the combined virologic and ALT response end point at week 24 in AZURE-1, with 56% response on 300 mg weekly and 45% on 900 mg every four weeks. The manufacturer projects a potential US launch in the fourth quarter of 2027.